000100:KRXYuhan Corporation Analysis
Data as of 2026-05-26 - not real-time
₩85,800.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Yuhan Corp. is trading at roughly KRW 85,800, well below its 20‑day SMA of KRW 88,160 and 50‑day SMA of KRW 93,106, confirming a bearish price momentum. The MACD histogram has turned positive but remains modest, RSI sits near the neutral 48 level, and the stock is hovering just above the identified support at KRW 80,000 while facing resistance near KRW 96,500. Technical signals therefore suggest limited upside in the near term.
Fundamentally, the company posts a solid 10% revenue growth and a modest dividend yield of 0.68% with a low payout ratio of 21%, indicating dividend sustainability. However, a DCF‑derived fair value of only KRW 20,284 versus the market price points to a significant overvaluation, compounded by high leverage (debt‑to‑equity ≈ 14.5) and negative free cash flow, raising concerns about long‑term financial resilience.
Fundamentally, the company posts a solid 10% revenue growth and a modest dividend yield of 0.68% with a low payout ratio of 21%, indicating dividend sustainability. However, a DCF‑derived fair value of only KRW 20,284 versus the market price points to a significant overvaluation, compounded by high leverage (debt‑to‑equity ≈ 14.5) and negative free cash flow, raising concerns about long‑term financial resilience.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below key moving averages indicating bearish momentum
- Proximity to support level with limited upside to resistance
- Significant overvaluation relative to DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential bounce off the KRW 80,000 support
- Sustainable dividend payout supporting investor yield
- Continued high leverage and negative free cash flow limiting upside
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Steady 10% revenue growth in a resilient healthcare sector
- Dividend sustainability despite modest yield
- Elevated debt burden and overvalued market price constraining long‑run returns
Key Metrics & Analysis
Financial Health
Revenue Growth10.10%
Profit Margin8.88%
P/E Ratio29.1
ROE8.21%
ROA2.14%
Debt/Equity14.53
Op. Cash Flow₩106.2B
Free Cash Flow₩-95031836672
Industry P/E27.5
Technical Analysis
TrendBearish
RSI48.5
Support₩80,000.00
Resistance₩96,500.00
MA 20₩88,160.00
MA 50₩93,106.00
MA 200₩109,031.00
MACDBullish
VolumeIncreasing
Fear & Greed Index90.84
Valuation
Fair Value₩20,284.16
Target Price₩136,450.00
Upside/Downside59.03%
GradeOvervalued
TypeGrowth
Dividend Yield0.68%
Risk Assessment
Beta0.85
Volatility34.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.